Garuda - Garba Rujukan Digital

p-Index From 2020 - 2025

3.701

P-Index

This Author published in this journals

All Journal Pharmaciana: Jurnal Kefarmasian JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Jurnal Penelitian Kesehatan Suara Forikes Belitung Nursing Journal JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) JSFK (Jurnal Sains Farmasi & Klinis) Jurnal Respirologi Indonesia Jurnal Ilmu Kefarmasian Indonesia Indonesian Journal of Cancer Eduvest - Journal of Universal Studies Jurnal Farmasi Indonesia Holistik Jurnal Kesehatan Jurnal Info Kesehatan Kesmas: Jurnal Kesehatan Masyarakat Nasional (National Public Health Journal)

Nadia Farhanah Syafhan

Division Of Clinical Pharmacy, Faculty Of Pharmacy, Universitas Indonesia, Depok 16424, West Java, Indonesia | Universitas Indonesia Hospital, Jl. Prof. DR. Bahder Djohan, Pondok Cina, Beji, Depok, West Java 16424, Indonesia

Author-ID : 4121410

Aerospace Engineering Biochemistry, Genetics & Molecular Biology Chemistry Computer Science & IT Dentistry Education Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Nursing Public Health Social Sciences Other

Published : 23 Documents Claim Missing Document

Claim Missing Document

Articles

1 2 3

Optimalisasi Manajemen Alat Pelindung Diri dan Pelayanan Farmasi Klinis selama Pandemi COVID-19: Narrative Review Kartika Citra Dewi Permata Sari; Nadia Farhanah Syafhan; Imanuel Sianipar
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 12, No 2
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.71090

Personal protective equipment (PPE) usage in health services plays an essential role in ensuring healthcare workers’ (HCW) and patients’ safety, especially during COVID-19 pandemic. On the other hand, the diversity of PPE types in the market, limited hospital budget and supplies, required PPE must be rationally managed. Pharmacists as supply managers and clinical care providers must implement PPE management optimization strategies to ensure PPE’s availability and avoid negative impacts such as increasing health service’s costs or PPE waste. This article aims to provide evidence-based strategies for PPE management in hospitals based on managing supply stages and clinical pharmacy services. The article was prepared using narrative literature review method from Google Scholar, ScienceDirect, and SpringerLink databases. Articles with topics related to PPE management; alternative uses of PPE, selection, planning, distribution, reuse, and clinical pharmacy services during the COVID-19 pandemic were included in this study. Based on the search, 30 articles and 13 policy guidelines were obtained which were included in this literature review. Management strategies included identifying and cohort supply need based on transmission risk, selecting PPE’s type, forecasting with calculation tools, avoiding just-in-time procurement, centrally distributed, and potential reuse. Clinical pharmacy services modification to minimize PPE use was also an optimizing strategy. For its implementation, pharmacists need to collaborate with other professionals in the hospital because it enhances success with a comprehensive approach. The recommended strategies are expected to assist the management of PPE in Indonesian hospitals, but its application must be tailored for each hospital.

Analisis Cost-Effectiveness Seftazidim Generik pada Pasien Kanker Payudara di Rumah Sakit Kanker “Dharmais” Jakarta, 2012 NADIA FARHANAH SYAFHAN; AGUSDINI BANUN SAPTANINGSIH; MUTIARA JEANY RAHAYU PERTIWI
Indonesian Journal of Cancer Vol 10, No 3 (2016): July - September 2016
Publisher : National Cancer Center - Dharmais Cancer Hospital

ABSTRACTAdministration of ceftazidime shortened duration of neutropenia and hospitalization days in breast cancer patients who had infection after myelosupressive chemotherapy. Cost-effectiveness analysis (CEA) as one of pharmacoeconomic methods was important to determine treatment attaining effect for lower cost. The aim of this study was to comparethe total direct medical cost and effectiveness, which was measured from length-of-stay (LOS), of generic ceftazidime A and B usage, and to decide which ceftazidime that was more cost-effective in early-stage and late-stage breast cancer patients at National Cancer Center Dharmais Hospital Jakarta year 2012. The study design was non-experimental withcomparative study retrospectively on secondary data from medical records and administrative data in 2012. Samples were taken by using total sampling method. The number of samples were 9 patients, which included 7 patients with generic ceftazidime A and 2 patients with generic ceftazidime B. The total direct medical cost of generic ceftazidime A in early-stage and late-stage breast cancer patients, respectively Rp 15.930.407,45 and Rp 15.962.519,25, were higher than generic B, respectively Rp 6.716.225,21 and Rp 7.147.956,92. Median LOS of generic A ceftazidime in early-stage and late-stage breast cancer patients, respectively 7 days and 10 days, were longer than generic B, respectively 3 days and 4 days. According to CEA result, generic ceftazidime B was more cost-effective than generic A.ABSTRAKPemberian seftazidim dapat mempersingkat durasi neutropenia dan lama hari rawat inap pada pasien kanker payudara yang mengalami infeksi setelah kemoterapi mielosupresif. Analisis cost-effectiveness merupakan salah satu metode farmakoekonomi yang penting untuk menentukan obat efektif dengan biaya yang lebih rendah. Penelitian dilakukan untuk membandingkan total biaya medis langsung dan efektivitas yang dilihat dari lama hari rawat penggunaan seftazidim generik A dan B, serta menentukan seftazidim yang lebih cost-effective pada pasien kanker payudara stadium awal dan lanjut di Rumah Sakit Kanker “Dharmais” Jakarta, 2012. Desain penelitian yang digunakan adalah studi komparatif secara retrospektif terhadap data rekam medis dan administrasi tahun 2012. Pengambilan sampel dilakukan secara total sampling. Jumlah pasien yang dilibatkan dalam analisis 9 pasien, yaitu 7 pasien menggunakan seftazidim generik A dan 2 pasien menggunakan seftazidim generik B. Median total biaya medis langsung kelompok generik A pada pasien kanker stadium awal maupun lanjut berturut-turut sebesar Rp 15.930.407,45 dan Rp 15.962.519,25 lebih tinggi dibanding generik B, berturut-turut sebesar Rp 6.716.225,21 dan Rp 7.147.956,92. Median lama hari rawat kelompok generik A pada pasien kanker stadium awal maupun lanjut berturut-turut 7 hari dan 10 hari, lebih panjang dibanding generik B, berturut-turut 3 hari dan 4 hari. Berdasarkan hasil penelitian disimpulkan bahwa seftazidim generik B lebih cost-effective dibanding generik A.

The Effect of Insulin Administration on Medication Adherence in Type 2 Diabetes Mellitus Patients with Neurological Complications July; Rani Sauriasari; Nadia Farhanah Syafhan; Hadijah Tahir
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 9 No. 3 (2022): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jfiki.v9i32022.242-251

Background: Medication adherence is essential to achieving controlled blood sugar in diabetic patients. Insulin generally provides better glycemic control but is considered painful and requires special techniques. Insulin administration in patients with neurological complications requires particular consideration because these complications can cause physical and cognitive barriers. Objective: This study analyses the effect of insulin administration on medication adherence in diabetic patients with neurological complications and the influence of various confounding variables (baseline characteristics, medical and medication history). Methods: This observational study was conducted with a cross-sectional design at a government hospital in East Jakarta from September 2021 to January 2022. The sample was type 2 diabetes mellitus patients with neurological complications who received antidiabetics for at least six months. The neurological complications include central nervous disorders (such as stroke) and peripheral nervous disorders (such as neuropathy). The independent variable was insulin administration, while the dependent variable was adherence, measured using subjective methods [Adherence to Refills and Medications Scale (ARMS)] and objective methods (Medication Refill Adherence (MRA) and HbA1c]. Results: Of 175 respondents, based on the three methods (MRA, ARMS, HbA1c), 13 respondents (7.4%) were adherent, namely one respondent (1.8%) in the insulin group and 12 respondents (10.1%) in the non-insulin group. Insulin administration affects adherence to antidiabetics by 0.123 times (95% CI: 0.015 - 1.024), or patients who use insulin have 87.7% lower adherence controlled by antidiabetic changes and the total number of medicines used. Conclusion: Insulin administration significantly affects medication adherence in diabetes mellitus patients with neurological complications.

Remdesivir in COVID-19: A Retrospective Analysis of Remdesivir Effectiveness and the Relation with Blood Type Variation Elsa Vera Denida Purba; Retnosari Andrajati; Nadia Farhanah Syafhan; Aditya Wirawan
Jurnal Respirologi Indonesia Vol 43, No 1 (2023)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v43i1.392

identify the profile of the effectiveness of Remdesivir (RDV) therapy and its relationship to blood type variations in COVID-19 patients at Universitas Indonesia Hospital (RSUI).Methods: Variations in blood types were examined for their influence on the effectiveness in Covid-19 infected patients with RDV as an antiviral treatment. Data for this study were acquired at RSUI using a retrospective cross-sectional method. The sample is infected patients with COVID-19 from January 2021 to December 2021 who received RDV therapy. The parameters of the effectiveness of the treatment was a reduction of minimally 2 points on the WHO Clinical Progression Scale after 14 days of Remdesivir administration.Results: RDV effectiveness percentage shows 57.5% of patients experienced clinical improvement. The analysis results of the effect of blood type variations on clinical outcomes significantly affect the effectiveness of RDV therapy (OR: 1.705, 95% CI: 1.091–2.665; p = 0.019) but insignificant in terms of mortality status (OR: 0.654, 95% CI: 0.383–1.117; p = 0.120).Conclusion: Blood type variations significantly affected the effectiveness of RDV therapy in infected COVID-19 patients.

Medication Adherence, Glycemic Control and Quality of Life in Patients with Type 2 Diabetes Mellitus: a cross-sectional study Delila Eliza; Nadia Farhanah Syafhan; Retnosari Andrajati; Sri Wulandah Fitriani
Jurnal Sains Farmasi & Klinis Vol 10, No 1 (2023): J Sains Farm Klin 10(1), April 2023
Publisher : Fakultas Farmasi Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/jsfk.10.1.21-27.2023

Medication adherence is important in controlling blood sugar levels (HbA1c) in patients with Diabetes Mellitus (DM). Studies on the relationship between medication adherence and blood sugar control on the quality of life (QoL) in Type 2 DM patients are limited in Indonesia. This study aims to assess the relation between medication adherence with blood sugar control and the quality of life of Type 2 DM patients. This study used a cross-sectional design conducted at Universitas Indonesia Hospital. It used Medication Adherence questionnaires and EuroQoL 5D-5L questionnaires to assess patients’ medication adherence and quality of life. This study involved a total of 74 Type 2 DM patients with an average age of 57 ± 10.74 years. Medication adherence with good blood sugar control (HbA1c <7%) showed a significant relationship (p-value <0.05) with COR values of 3.74 (1.21 - 11.6) compared to non-adherent patients. But not on the QoL Index and VAS (Visual Analog Scale) values, where the value is lower in patients with high adherence and good blood sugar control. Factor asscociated with blood sugar controlled were comorbidites and medication adhrence while factor that associated with quality of life were comorbidities, ages, education and employment status

Adverse Events Following Immunization of mRNA and Inactivated Vaccines Against COVID-19 at Universitas Indonesia Hospital: A Cross-Sectional Study Vriona Ade Maenkar; Retnosari Andrajati; Nadia Farhanah Syafhan
Jurnal Respirologi Indonesia Vol 43, No 2 (2023)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v43i2.429

Background: The coronavirus that causes severe acute respiratory syndrome (COVID-19) is coronavirus 2 (SARS-CoV- 2). This virus has caused a global pandemic. The adverse impact of this virus in the past two years has resulted in efforts to build herd immunity through vaccination. This study aimed to identify the side effects after getting the Pfizer and Sinovac vaccines at the Universitas Indonesia Hospital and the risk factors for Adverse Events Following Immunization (AEFI).Methods: This observational study used a descriptive, non-experimental method with a cross-sectional design. Google Forms was used to collect data.Results: The onset of AEFI symptoms ranged from 15 minutes to 24 hours. The common AEFI symptoms were pain at the injection site, fatigue, muscle aches, and joint pain. The AEFI severity was mostly at the mild level, and only a few participants took medication. Female participants, participants with comorbidities and allergies, previous medication histories within the last 6 months, and those with experience of COVID-19 had a higher risk for AEFI with a statistically significant effect (P <0.005).Conclusion: This study revealed that Pfizer and Sinovac COVID-19 vaccines were safe to administer as the AEFIs were mostly mild and automatically disappeared and decreased after 1 to 3 days.

Faktor-Faktor yang Memengaruhi Efektivitas Hematinik pada Pasien Hamil di Puskesmas Kecamatan Matraman Nadia Farhanah Syafhan; Meiliani Shara Suria L; Azizahwati
JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X Vol. 12 No. 1 (2020): Jurnal Farmasi Indonesia
Publisher : Pengurus Pusat Ikatan Apoteker Indonesia

The government has been giving hematinic that contains 200 mg of ferro sulfas and 0.25 mg of folic acid to pregnant patient since 1970, but anaemia prevalence in pregnant patient at Matraman primary health care has been still relatively high. This research aimed to analyze factors that were influencing hematinic effectiveness that has been used by pregnant patient at Matraman primary health care. The method used for this research was cross-sectional study with purposive sampling technique. Data was obtained from the result of laboratory test for haemoglobin level and interview using valid and reliable questionnaire. Respondents of this research were pregnant patient who used hematinics that were given from government and their haemoglobin level had been measured at least twice during their pregnancy. Total respondent who met the inclusion criteria were 85 patients. Based on the result, there were significant association between tea consumption habits and haemoglobin level (p=0.000) and also significant association between patient adherence on hematinic consumption and haemoglobin level (p=0.004). But there were no significant association between dietary habit and haemoglobin level (p=0,105) and between how to consume hematinic and haemoglobin level (p=0,684). This study showed factors influencing hematinic effectiveness were tea consumption habits and patient adherence on hematinic consumption.

Effectiveness of COVID-19 Antivirus Therapy and Its Relationship with Vaccination: A Retrospective Analysis Andi Utari Prasetya Ningrum; Retnosari Andrajati; Nadia Farhanah Syafhan; Aditya Wirawan
Jurnal Respirologi Indonesia Vol 43, No 3 (2023)
Publisher : Perhimpunan Dokter Paru Indonesia (PDPI)/The Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/jri.v43i3.434

Background: COVID-19 is known to have infected more than a million people. COVID-19 can be treated with antivirals. Besides antiviral drugs, vaccination becomes one of the strategies to suppress the spread of COVID-19. This study aimed to analyze the effectiveness of antivirus and the relationship between vaccination and the effectiveness of the two antiviral therapies in COVID-19 patients based on improvements in the patient's clinical condition, length of stay, and mortality.Methods: This study used a retrospective cohort design conducted at the Universitas Indonesia Hospital, Depok, Indonesia. Data were taken from medical records and hospital databases from January 2021 to August 2022. The antivirals in this study were remdesivir and favipiravir. The samples were divided into two groups, namely the vaccinated and unvaccinated groups.Results: The factor affecting the effectiveness of remdesivir and favipiravir therapy was the severity of COVID-19. It was shown that vaccination had a significant effect on improving clinical conditions, reducing length of stay, and reducing mortality in patients treated with remdesivir who had been vaccinated compared to those who had not been vaccinated. In patients who received favipiravir therapy and were vaccinated, it also showed an effect on improving clinical conditions, length of stay, and mortality compared to patients who were not vaccinated, although the results were not statistically significant.Conclusion: Vaccination had a positive effect on the effectiveness of remdesivir and favipiravir in COVID-19 patients, which could improve the patient's clinical condition in a better direction, as well as reduce length of hospitalization and mortality.

Clinical profile, treatment, and outcomes of patients with COVID-19 in a tertiary referral hospital in South Sumatera, Indonesia: A retrospective single-center study Deli Marteka; Amarila Malik; Ingrid Faustine; Nadia Farhanah Syafhan
Belitung Nursing Journal Vol. 8 No. 6 (2022): November - December
Publisher : Belitung Raya Foundation, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33546/bnj.2302

Background: Although there are fewer COVID-19 cases in Indonesia, the pandemic is still ongoing. COVID-19 has a significant death rate in Indonesia, but lack of information on the effect of different clinical and demographic factors on COVID-19-related grimness and mortality in Indonesia. Objective: This study examined the clinical profile, treatment, and outcomes of patients with COVID-19 at Lahat Regency Hospital in South Sumatera, Indonesia, to find relevant markers that might be utilized to predict the prognosis of these patients. Methods: This was a retrospective single-center study of all medical record files of confirmed patients with COVID-19 admitted to Lahat Hospital from September 2020 to August 2021 (n = 285). Descriptive statistics, Chi-square, Mann-Whitney, Multiple Logistic Regression, and Cox's proportional hazards model were used for data analyses. Results: This study included 65 non-hospitalized and 220 hospitalized patients. Hospitalized patients were divided into dead and alive groups. The median age was lower in the non-hospitalized group without gender discrimination, and most hospitalized patients had comorbidities. Vital signs and clinical features were significantly different in hospitalized patients compared to non-hospitalized. The survival patients in the hospitalized group showed lower white blood cell (WBC), neutrophil percentages, and neutrophil-lymphocyte ratio (NLR) but higher lymphocyte and eosinophil. Non-survival patients had elevated alanine aminotransferase (ALT), blood urea nitrogen (BUN), creatinine, blood glucose, and potassium. The use of Favipiravir and Remdesivir was significant between the alive and dead groups. The mean hospital stay for all patients was 9.49 ± 4.77 days, while the median duration of hospital time was 10.73 ± 4.33 days in the survival group and 5.39 ± 3.78 days in the non-survival group. Multiple logistic regression analysis determined respiration rate, WBC, and BUN as predictors of survival. Conclusions: Age and comorbidities are significant elements impacting the seriousness of COVID-19. Abnormal signs in laboratory markers can be used as early warning and prognostic signs to prevent severity and death. Potential biomarkers at various degrees in patients with COVID-19 may also aid healthcare professionals in providing precision medicine and nursing.

Reaksi Merugikan Obat Kanker Berbasis Antrasiklin pada Pasien Kanker Payudara di RS Kanker Dharmais Chairunnisa, Dian Fitri; Harahap, Yahdiana; Syafhan, Nadia Farhanah; Purwanto, Denni Joko
JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X Vol. 16 No. 1 (2024): Jurnal Farmasi Indonesia
Publisher : Pengurus Pusat Ikatan Apoteker Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35617/jfionline.v16i1.164

Breast cancer is the type of cancer that most often affects women worldwide. Doxorubicin is an anthracycline class, a first-line anticancer therapy with clinical activity in breast cancer. Doxorubicin can cause cardiotoxic effects due to the formation of doxorubicinol as its primary metabolite. Adverse drug reactions also vary depending on the chemotherapy regimen. This study aimed to determine the adverse reactions to anthracycline-based drugs that breast cancer patients often experience. This observational descriptive study was conducted from April to July 2022 at the Dharmais Cancer Hospital, Jakarta. The sample in this study was breast cancer patients undergoing chemotherapy with anthracycline-based regimens. Data were collected through interviews and observation of medical records, which were analyzed by univariate analysis. The results showed that the most frequent drug reaction was alopecia, with a percentage of 97.1%. They were followed by nausea at 85.7%, vomiting at 71.4% and pain at 65.7%. The fastest time for nausea to appear is within 18-24 hours (peak days 2 to 3) after chemotherapy. Did not experience a decrease in left ventricular ejection fraction by 34.3%, and 65.7% experienced a reduction in left ventricular ejection fraction after doxorubicin chemotherapy. Patients who underwent a reduction in left ventricular ejection fraction after doxorubicin chemotherapy had a decrease in ejection fraction <10%, and no patients experienced a decline in left ventricular ejection fraction >10%. Breast cancer patients who receive anthracycline-based treatment can experience adverse drug reactions, including nausea, vomiting, alopecia, pain and decreased left ventricular ejection fraction.

Co-Authors Abu Rachman Adil khan, Muhammad Aditya Wirawan Adityo Susilo, Adityo Afina Nur Fauziyyah AGUSDINI BANUN SAPTANINGSIH Aldora, Ghea Shafa Amarila Malik Andi Utari Prasetya Ningrum Andrajati, Retnosari Ariesa Oktamauri Azizahwati Bambang Karsono Bambang Wispriyono Chairunnisa, Dian Fitri Deli Marteka Delila Eliza DENNI JOKO PURWANTO, DENNI JOKO Dinda Bestari Sutantoputri Djuria, Rachmawati Felani Eliza, Delila Elsa Vera Denida Purba Farmasita Budiastuti, Rizky Fauzi, Muhamad Andhika Habibie, Taufan Harun Hadijah Tahir Hadiwati, Rangkay Hindun Wilda Risni Hindun Wilda Risni Imaniar, Rania Imanuel Sianipar Ingrid Faustine July Kamila, Shinta Kartika Citra Dewi Permata Sari Kartika Citra Dewi Permata Sari Kusumawardani, Larasati Arrum Meiliani Shara Suria L MUTIARA JEANY RAHAYU PERTIWI Nadhila Hasna Hanifah Nasution, Izza Aulia Rizqika Nisa Maria Noor, Sidra Prasetyaningrum, Marchen Pukovisa Prawiroharjo Pukovisa Prawiroharjo, Pukovisa Purnama Putri, Raden Jacinda Yasmin Rachman, Abu Rachmawati Felani Djuria Rani Sauriasari Rani Sauriasari Rani Sauriasari, Rani Retnosari Andrajati Retnosari Andrajati Retnosari Andrajati Retnosari Andrajati Retnosari Andrajati Retnosari Andrajati Risni, Hindun Wilda Salsabila, Azzahra Fahira Santi Purna Sari Sri Wulandah Fitriani Sri Wulandah Fitriani Sri Wulandah Fitriani, Sri Wulandah Vriona Ade Maenkar Wahono, Dwi Edi Yahdiana Harahap

Title

Found 23 Documents
Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title Search

Found 23 Documents Search

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Title

Found 23 Documents
Search